Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2017 1
2018 3
2019 5
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.
Collins DM, Conlon NT, Kannan S, Verma CS, Eli LD, Lalani AS, Crown J. Collins DM, et al. Cancers (Basel). 2019 May 28;11(6):737. doi: 10.3390/cancers11060737. Cancers (Basel). 2019. PMID: 31141894 Free PMC article. Review.
Acquired Resistance to Antibody-Drug Conjugates.
Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Collins DM, et al. Cancers (Basel). 2019 Mar 20;11(3):394. doi: 10.3390/cancers11030394. Cancers (Basel). 2019. PMID: 30897808 Free PMC article. Review.
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A, Ivers L, Conlon NT, Pedersen K, Gaynor N, Browne BC, O'Brien NA, Gullo G, Collins DM, O'Donovan N, Crown J. Canonici A, et al. Among authors: collins dm. Invest New Drugs. 2019 Jun;37(3):441-451. doi: 10.1007/s10637-018-0649-y. Epub 2018 Jul 30. Invest New Drugs. 2019. PMID: 30062574
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
Gullo G, J Eustace A, Canonici A, M Collins D, Kennedy MJ, Grogan L, Breathhnach O, McCaffrey J, Keane M, Martin MJ, Gupta R, Leonard G, O'Connor M, Calvert PM, Donnellan P, Walshe J, McDermott E, Scott K, Hernando A, Parker I, W Murray D, C O'Farrell A, Maratha A, Dicker P, Rafferty M, Murphy V, O'Donovan N, M Gallagher W, Ky B, Tryfonopoulos D, Moulton B, T Byrne A, Crown J. Gullo G, et al. Among authors: m collins d. Ther Adv Med Oncol. 2019 Jul 24;11:1758835919864236. doi: 10.1177/1758835919864236. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31384312 Free PMC article.
Innovative Technologies Changing Cancer Treatment.
Charmsaz S, Prencipe M, Kiely M, Pidgeon GP, Collins DM. Charmsaz S, et al. Among authors: collins dm. Cancers (Basel). 2018 Jun 19;10(6):208. doi: 10.3390/cancers10060208. Cancers (Basel). 2018. PMID: 29921753 Free PMC article.
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
Canonici A, Qadir Z, Conlon NT, Collins DM, O'Brien NA, Walsh N, Eustace AJ, O'Donovan N, Crown J. Canonici A, et al. Among authors: collins dm. Invest New Drugs. 2018 Aug;36(4):581-589. doi: 10.1007/s10637-017-0556-7. Epub 2018 Feb 2. Invest New Drugs. 2018. PMID: 29396630
Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference.
Charmsaz S, Collins DM, Perry AS, Prencipe M. Charmsaz S, et al. Among authors: collins dm. Cancers (Basel). 2019 Aug 7;11(8):1125. doi: 10.3390/cancers11081125. Cancers (Basel). 2019. PMID: 31394729 Free PMC article.
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.
Gaynor N, Crown J, Collins DM. Gaynor N, et al. Among authors: collins dm. Semin Cancer Biol. 2020 Jul 2:S1044-579X(20)30152-8. doi: 10.1016/j.semcancer.2020.06.016. Online ahead of print. Semin Cancer Biol. 2020. PMID: 32623044 Free article. Review.
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O'Byrne KJ, O'Donovan N, Crown J. Collins DM, et al. Cell Immunol. 2017 Sep;319:35-42. doi: 10.1016/j.cellimm.2017.07.005. Epub 2017 Jul 15. Cell Immunol. 2017. PMID: 28735814
Modulation of P-gp expression by lapatinib.
Dunne G, Breen L, Collins DM, Roche S, Clynes M, O'Connor R. Dunne G, et al. Among authors: collins dm. Invest New Drugs. 2011 Dec;29(6):1284-93. doi: 10.1007/s10637-010-9482-7. Epub 2010 Jul 6. Invest New Drugs. 2011. PMID: 20607587
11 results
Jump to page
Feedback